Engineered T Cells Market to Grow with a CAGR of 27.60% through 2028
Strategic
collaborations, increased investment, and global expansion efforts are expected
to drive the Global Engineered T Cells Market growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Engineered T Cells Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2028”, the
Global Engineered T Cells Market stood at USD 2542.77 million in 2022 and is
anticipated to grow with a CAGR of 27.60% in the forecast period, 2024-2028. This
can be attributed to strategic partnerships and collaborations. Pharmaceutical
and biotechnology companies have formed strategic partnerships and
collaborations to accelerate the development and commercialization of
engineered T cell therapies. These partnerships bring together the expertise
and resources necessary to navigate the complex regulatory landscape, scale up
manufacturing, and ensure wider patient access.
Furthermore,
engineered T cell therapies are expanding their presence beyond traditional
markets like the United States and Europe. Clinical trials and
commercialization efforts are reaching new regions, increasing the global reach
of these innovative treatments.
The Engineered T
cells market encompasses services designed to enhance the capabilities of
genetic engineering techniques. Engineered T cells are a subset of the broader
field of immunotherapy, which is a rapidly advancing domain within medical
research and treatment. Notably, engineered T cells have shown success in
treating certain cancers like leukemia and lymphoma by effectively targeting
and eliminating cancer cells. Additionally, there is potential for the
application of engineered T cells in the treatment of viral diseases such as
HIV and hepatitis.
The application
of genetically modified T cells has demonstrated remarkable effectiveness in
combatting leukemia and lymphoma, which are both blood malignancies. Moreover,
engineered T cells are often used in combination with other treatments like
chemotherapy, radiation therapy, and checkpoint inhibitors to enhance their
efficacy. The increasing incidence of leukemia is expected to drive market
growth during the forecasted period. For instance, according to data from the
Leukemia and Lymphoma Society, approximately 59,610 new cases of leukemia are
expected to be diagnosed.
The Global Engineered
T Cells Market is segmented into type, application, end-user, regional
distribution, and company.
Based on its end-user,
the hospitals sector is anticipated to be the predominant player in the
engineered T cells market. Hospitals are well-equipped to lead in this domain
due to their abundance of clinical expertise and a highly trained medical
workforce. The administration and treatment of complex engineered T-cell
therapies involve intricate procedures, meticulous patient monitoring, and risk
management. The successful implementation of engineered T-cell therapies
demands collaboration among various medical specialties, including oncologists,
hematologists, immunologists, and geneticists, among others. The ongoing
interdisciplinary teamwork fostered by hospitals contributes to enhanced
patient care and improved therapeutic outcomes. Patients with serious medical
conditions often turn to hospitals as their primary healthcare destination.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Engineered T Cells Market.”
Concurrently,
the cancer research centers sector is poised for substantial growth within the
engineered T cells market during the projected period. These dedicated
institutions engaged in cancer research are positioned to conduct advanced
investigations into modified T-cell treatments, thanks to their access to
valuable resources and extensive knowledge. Their research efforts play a
pivotal role in advancing treatment outcomes, offering invaluable insights into
the conception, development, and refinement of these therapies. Furthermore,
these centers rigorously conduct clinical trials to assess the safety and
effectiveness of engineered T-cell treatments.
Based on region,
North America held the largest share of revenue in the engineered T cells
market in 2022, and this dominant position is expected to persist throughout
the projected period. North America is home to some of the world's leading
pharmaceutical and biotechnology firms. These companies have made substantial
investments in the research of modified T cells, paving the way for
groundbreaking treatments and tools. The healthcare system in North America is
well-established and boasts prestigious hospitals, clinics, and medical
research facilities. This robust infrastructure facilitates the development and
testing of new treatments, including modified T cells, in patients.
Meanwhile,
the Asia Pacific region is poised to experience the fastest growth in the
engineered T cells market during the forecasted period. The increasing
incidence of cancer and other chronic diseases in Asia has elevated the demand
for innovative and personalized therapies like modified T-cell treatments. The
vast and diverse population of the Asia Pacific region provides a substantial
pool of patients for clinical trials and the adoption of these treatments.
Moreover, developed nations such as China, Japan, South Korea, and India have
been actively developing and marketing engineered T-cell therapies due to
enhancements in healthcare infrastructure and biotechnology research capabilities.
Major companies
operating in Global Engineered T Cells Market are:
- Amgen Inc
- Athenex, Inc.
- Bellicum Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- Eli Lilly & Co
- Gilead Sciences Inc
- Novartis AG
- Oxford Biomedica PLC
- Pfizer Inc
- Precision BioSciences Inc
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The global
engineered T cells market is poised for continued growth and innovation, with
the emerging trends shaping its future. Expansion into solid tumors,
combination therapies, off-the-shelf CAR-T, next-generation CARs, gene editing
techniques, streamlined regulations, global expansion, increased investment,
patient advocacy, and real-world evidence are key areas to watch. As these
trends continue to develop, they have the potential to further improve patient
outcomes, expand accessibility, and solidify the position of engineered T cell
therapies as a cornerstone of modern medicine,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Engineered T Cells Market By Type
(Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes),
By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer,
Melanoma), By End-User (Cancer Research Centers, Clinics, Hospitals, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”,
has evaluated the future growth potential of Global Engineered T Cells Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Engineered T Cells Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com